Let's Get Started

News

Friday Feb 3rd, All eyes on MDJH our low float momentum play!

Friday Feb 3rd, All eyes on MDJH our low float momentum play!

Feb 2, 2023

Pull up MDJH now, super low float momentum play for Friday, tomorrow, Feb 3rd.

The float is super low at 1.4M shares!

This stock has a history of 100% gains with very low volume.

MDJH should be very active in the morning, so be ready!

The definition of a momentum play is:

when you buy a stock because the stock is moving big and you are hoping to scalp a quick gain if the move continues.

We think this is going to be “moving big” at the morning bell.

Remember, this stock moves very fast on a few trades.

So be ready tomorrow morning!

We have identified 2 catalysts revealing the hidden potential with MDJH.

Before we go over the catalysts, let’s do a quick summary on MDJM Ltd (NASDAQ: MDJH)

MDJM Ltd Company Summary

Company Name: MDJM Ltd

Ticker: MDJH

Exchange: NASDAQ

Website: http://ir.mdjmjh.com/

MDJM Ltd Growing Systems Company Summary:

Founded in 2002 and headquartered in Tianjin, China, Mingda Tianjin is an emerging, integrated real estate services company in China.

We primarily provide primary real estate agency services to our real estate developer clients, and provide, on an as-needed basis, real estate consulting services, and independent training services.

MDJM Ltd.

MDJH Has Two Catalysts That Could Send It To The Moon Tomorrow

#1 Low Float

#2 Small amount of volume makes it explode

MDJH

LOW supply & HIGH Demand = Massive PPS Increases, it’s simple math!

Stock MDJH has ONLY 1.4M shares in the float.

Our last two alerts traded 1M shares each, that would almost be the WHOLE FLOAT!

Our subscribers have an amazing opportunity!

What do we mean by, “our subscribers have an amazing opportunity!”?

We love low float stocks because of their ability to MOVE.

They provide great upside opportunities for day traders.

What is a “low float stock”?

Low float stocks are those with a low number of shares. Floating stock is calculated by subtracting closely-held shares and restricted stock from a firm’s total outstanding shares. Closely-held shares are those owned by insiders, major shareholders, and employees.

MDJH has only 1.4M shares in the float.

While the average NASDAQ float we normally feature is 10M shares, 10X higher!

This stock has very little supply of shares in the market and our subscribers normally create a large amount of demand.

Remember, LOW supply & HIGH Demand = Massive PPS Increases, it’s simple math!

Mdjh

MDJH

On August 2nd of last year MDJH traded around our average volume of 1.7M shares and went up almost 100%!

That day went like this, someone invested $10,000 and had $20,000 in just a few hours.

Again, our average alerts trade 1-2M shares

The last time MDJH had that kind of volume was in August and went up almost 100%!

Let’s Recap The Two Catalysts That Could Send It To The Moon Tomorrow

#1 Low Float

#2 Small amount of volume makes it explode

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has not been compensated for profiling MDJH. We own ZERO shares in MDJH.

Full Disclaimer

read more
FLGC Stock: Flora Growth (NASDAQ:FLGC) Gains Momentum On Revenue Growth: Will It Sustain?

FLGC Stock: Flora Growth (NASDAQ:FLGC) Gains Momentum On Revenue Growth: Will It Sustain?

Feb 2, 2023

A stock that has managed to come onto the surface following a strong move over the course of the past few days is FLGC stock. Flora Growth Corp (NASDAQ:FLGC), which is involved in the outdoor cultivation, manufacturing, and distribution of cannabis products, was in the news earlier on in the week.

Flora Growth Corp

Company Name: Flora Growth Corp

Ticker: FLGC

Exchange: NASDAQ

Website: https://www.floragrowth.com

Flora Growth Corp Summary:

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands designed to deliver the most compelling customer experiences in the world, one community at a time.

As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions.

Now, let’s analyze the latest news from FLGC stock:-

#1 Expects 100% Topline Growth For Fiscal 2023

On Monday the company announced that it expected its revenues for the fiscal year of 2023 to be in the $90 million to $105 million range. It was a significant new announcement from the company and on the day of the announcement the stock clocked gains of as much as 40%. In this regard, it should also be noted that a survey by FactSet expected the company to post revenues of $95.6 million for the year.

The company included the revenues that were projected from its new acquisition Franchise Global Health, a Germany-based business, in its projections.

FLGC stock reacted bullishly after the news.

#2 Gets Additional 180 Day Extension by Nasdaq to Regain Compliance

Earlier on in the month of January 2023, the company had come into the news once again after it announced that it had got an extension of 180 days from NASDAQ so as to fulfill the $1 minimum bid price requirement that is part of the listing rules of the exchange.

The initial period of 180 days to regain compliance expired back on January 4, 2023. The extension could be construed as a positive development for the company as it tries to stay listed on the exchange.

#3 Acquisition of Franchise Global Health

The acquisition of Franchise Global Health, which had been completed in December last year could well be a cornerstone for the company’s growth.

Thanks to the acquisition the company is going to establish a presence in the fast-growing German market and sell medical cannabis through more than 1200 pharmacies as well as distribution outlets spread across 28 nations. Franchise Global Health generated a gross profit of C$2.8 million and revenues of C$42 million in the nine-month period that ended on September 30, 2022.

After the recent rally, the stock might find resistance at a higher lever, and profit booking may be healthy for now.

Take a look at the CIFR stock, which is flying after a key update.

read more
OPEN Stock: Opendoor Technologies Inc (NASDAQ:OPEN) Bounces Back: Will It Continue?

OPEN Stock: Opendoor Technologies Inc (NASDAQ:OPEN) Bounces Back: Will It Continue?

Feb 1, 2023

Residential real estate transaction platform operator Opendoor Technologies Inc (NASDAQ:OPEN) is one of the more innovative companies at the moment and the OPEN stock has been in the middle of a strong ride in recent weeks. The stock has continued to climb in the past week during the course of which it went up by 38%.

That took the gains made in the past month to as much as 98% as the OPEN stock ended up hitting its highest level in many months.

Opendoor Technologies Inc

Company Name: Opendoor Technologies Inc

Ticker: OPEN

Exchange: NASDAQ

Website: https://www.opendoor.com

Opendoor Technologies Inc Summary:

Opendoor Technologies Inc. operates a digital platform for residential real estate in the United States. The company’s platform enables consumers to buy and sell a home online. It also provides title insurance and escrow services. Opendoor Technologies Inc. was incorporated in 2013 and is based in Tempe, Arizona.

Now, let’s review the latest news from the company:-

#1 Q4 Earnings On Radar – All eyes on OPEN stock

All eyes are now going to be on the company’s fourth-quarter financial results and it may be a good time to keep an eye on the Opendoor stock in the lead-up to the day.

On January 26 the company announced that it was going to announce its financial results for the fourth fiscal quarter that ended on December 31, 2022, on February 23, 2023. On top of that, the management would also host a conference call to discuss the financial results and other operations. The conference call would be available on a live webcast at 2 pm PT.

It would be keenly watched, how the OPEN stock would react after earnings.

#2 Opendoor Shuffles Leadership, Appoints New CEO

The performance in the third quarter of Opendoor may have triggered a change in the management as well and back on December 2, 2022, the company made such an announcement. It announced that it had appointed a new Chief Executive Officer in the form of Carrie Wheeler.

Wheeler had previously been the Chief Financial Officer at Opendoor. The shakeup at the top echelons in the management had initially led to a selloff in the stock. Wheeler was also made a member of the board of directors of the company with immediate effect.

#3 Why The OPEN stock Fell Last Year

Last year, the stock had gone through a tough time as the weakness in demand and plunging home prices took their toll. In the third quarter, the company’s performance had been disappointing and that resulted in a 20% drop in the stock price. That took the cumulative loss in a 12-month period to 88%.

Keep an eye on OPEN stock and it would be interesting to see if the stock reverses its losses from the last year.

read more
TCBP Stock: TC BioPharm (NASDAQ:TCBP) Stock On Radar Ahead of A Key Event

TCBP Stock: TC BioPharm (NASDAQ:TCBP) Stock On Radar Ahead of A Key Event

Jan 31, 2023

Clinical-stage biotech company TC BioPharm (NASDAQ:TCBP) has seen it’s stock considerable momentum over the course of the past month and it could well be a good time to start taking a deeper look into it. In the past week, TCBP stock clocked gains of 13% and that took the gains made by it over the course of the past month to as much as 40%.

The company is mainly involved in the development of platform allogeneic gamma-delta T cell therapies which are meant for treating cancer.

TC BioPharm

Company Name: TC BioPharm

Ticker: TCBP

Exchange: NASDAQ

Website: https://www.tcbiopharm.com/

Adamas One Corp Summary:

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

Here are the latest news from TCBP stock:-

#1 All Eyes On Shareholder Update Call

The company was in the news last week on January 20 when it announced that it was going to come up with a shareholder update on February 20, 2023, at 10 in the morning Eastern Standard Time.

In that particular update, the management of TC BioPharm would be looking to provide a detailed update with regard to the trial plan for the allogeneic gamma delta therapeutic in different oncology indications. There will also be a question and answer session after CFO Martin Thorp and CEO Bryan Kobel complete their remarks.

It would be interesting to see how would TCBP stock react after the event.

#2 Receives Notice of Non-compliance with NASDAQ’s Listing Rule 5550(b)(1)

On January 19, it emerged that TC BioPharm had been provided with a written notification from NASDAQ with regards to the fact that it had failed to regain compliance as per the minimum Market Value of Listed Securities threshold of $35,000,000. That figure is the minimum for continued listing on the exchange.

The company announced at the time that it was going to present the exchange with a comprehensive plan on how it was going to address the situation and regain compliance.

#3 Strategic Collaboration to Advance Gamma Delta T Cells in Oncology

Another major development with regards to TC BioPharm was the announcement from the company earlier this month on January 17 that it had decided to get into collaboration with the celebrated University of Texas MD Anderson Cancer Center.

The collaboration would be focussed on expanding the knowledge with regard to the deployment of gamma-delta T cells in oncology. It remains to be seen if TCBP stock can hold onto its momentum this week.

So, keep an eye on TCBP stock as shareholders would reach to the company’s upcoming earnings and we may see high volatility. Get more lists of stocks here

read more
JEWL Stock: Adamas One Corp (NASDAQ:JEWL) On Watchlist After Recent Fall

JEWL Stock: Adamas One Corp (NASDAQ:JEWL) On Watchlist After Recent Fall

Jan 27, 2023

Technology has influenced most industries in the world in a big way and in this regard, even the jewelry industry is no exception. In this context, it may be a good time for JEWL stock investors to look into Adamas One Corp (NASDAQ:JEWL), which has emerged as one of the more innovative companies in the industry.

The company has managed to leverage technology to create lab-created diamonds, which can be used both for making jewelry and also for industrial purposes.

Adamas One Corp

Company Name: Adamas One Corp

Ticker: JEWL

Exchange: NASDAQ

Website: https://www.adamasone.com

Adamas One Corp Summary:

Adamas One Corp., a diamond company, produces single crystal diamonds and diamond materials for diamond jewelry industry and industrial markets in the United States and internationally. The company was incorporated in 2018 and is based in Scottsdale, Arizona.

Here are the latest news from JEWL stock:-

 #1 Influencer TRAX NYC Visits Adamas One South Carolina Factory

Last week on January 19, the company was in the news after it announced that TRAX NYC, a jewellery influence had gone on a video tour of its facility in Greenville, South Carolina, and posted a video on Instagram.

The video had proven to be a roaring success and within the first hour it had clocked as many as 200,000 views. Such a video could often prove to be a potent marketing campaign in the age of social media and it could only be seen as a positive for Adamas One.

JEWL stock reacted muted to the news.

#2 Reports Initial Diamond Sales for Fiscal Year 2022

On January 18, the company came into the news cycle once again when it announced its financial results for the fiscal year that ended on September 30, 2022. The company noted that during that financial year, it had managed to sell as much as $1.78 million worth of its lab-grown diamonds.

That was a major turnaround considering the fact that in the previous fiscal year, the total sales had stood at $0.

#3 Newly Lists Stock – Forms Base After Recent Fall

The company started its marketing campaign in the middle of the second quarter and hence, most of the sales was closed in the final seven months of the fiscal year. That came as a significant boost as well considering the fact that Adamas One was listed on the JEWL stock market back on December 16, 2022, in an initial public offering worth $11 million.

read more
NMRD Stock: Why is Nemaura Medical (NASDAQ: NMRD) A Top Stock To Watch in February?

NMRD Stock: Why is Nemaura Medical (NASDAQ: NMRD) A Top Stock To Watch in February?

Jan 26, 2023

Over the past week, the Nemaura Medical Inc (NASDAQ: NMRD) stock has been in the middle of a solid rally and recorded gains of 56% to emerging as one of the stock to watch. As it happens, the NMRD stock hit its highest level since mid-October last year.

Nemaura Medical Inc

Company Name: Nemaura Medical Inc

Ticker: NMRD

Exchange: NASDAQ

Website: https://nemauramedical.com

Nemaura Medical Inc Summary:

Nemaura Medical Inc. is a medical technology company developing and commercialising non-invasive wearable diagnostic devices. The Company is currently also commercialising sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, as a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse, and prevent the onset of diabetes.

There are certain specific triggers that led to the remarkable rally in the NMRD stock.

#1 Medical’s Program Shows Weight Loss In 100% Of Participants

One of those came about earlier in the week on January 24 when the company announced the initial results from the patient studies that had been conducted with the National Health Service (NHS) of the United Kingdom for Miboko, its metabolic health program.

The results were positive as the patients recorded an average weight loss of 3.7 pounds and all the patients experienced some degree of weight improvement.

This news had a major positive impact on NMRD stock and is one of the top stock to watch.

#2 Commences Pilot Program of Miboko with the NHS

While that was quite clearly a significant development it should be noted that the announcement with regards to the study for Miboko in collaboration with the NHS had been announced back on November 29, 2022.

Mikobo is the first product in its category to have a non-invasive glucose sensor in a lifestyle app. It not includes information with regard to drinking and good intake but also provides analytics and educational content. At the end of the analysis, the app provides the user with a metabolic score based on diet and other important factors.

#3 Solid Industry Growth

Nemaura is entering the Continuous Glucose Monitoring Market with the product and it is a market that is expanding rapidly. The market was worth as much as $6.13 billion back in 2021 and by 2030 it is expected to command a valuation of $16.33 billion, which reflects a CAGR of 17.33%.

So, considering the latest news and big jump, NMRD stock is one of the other top stock to watch for the month of February.

read more
A2Z Smart Technologies (NASDAQ:AZ) Is The Stock to Watch Following Multiple News

A2Z Smart Technologies (NASDAQ:AZ) Is The Stock to Watch Following Multiple News

Jan 25, 2023

At this point in time, investors are hotly on the trail of A2Z Smart Technologies Corp (NASDAQ:AZ) and that becomes apparent when one looks into the price action in the stock and is the notable stock to watch. Over the course of the past week alone, AZ stock has clocked gains of 43% and that took the gains over the past month to as much as 92%.

Why Such a Big Jump?

AZ stock has been witnessing continuous buying after announcing multiple news. Firstly, the stock reached a key partnership with Lenovo Group Limited. Secondly, the company announced a launch of a new Smart Cart model.

A2Z Smart Technologies Corp

Company Name: A2Z Smart Technologies Corp

Ticker: AZ

Exchange: NASDAQ

Website: https://a2zas.com/

A2Z Smart Technologies Corp Summary:

A2Z Smart Technologies Corp. creates innovative solutions for complex challenges. A2Z’s flagship product is an advanced proven-in-use mobile self-checkout shopping cart.

With its user-friendly smart algorithm, touch screen, and computer-vision system, Cust2Mate streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply “pick & go”, and bypass long cashier checkout lines. This results in a more efficient shopping experience for customers, less unused shelf-space and manpower requirements, and advanced command and control capabilities for store managers.

As AZ stock has soared over the past month, let’s analyze the key catalysts:-

#1 Big Partnership With Lenovo Group

Last Friday, the company announced that its subsidiary has partnered with Lenovo Group Limited. As per the joint venture, A2Z Smart Technologies will use Lenovo solutions in its revolutionary Cust2mate Smart Cart solution and Lenovo will actively sell and promote the solution through its extensive worldwide channels.

Hila Kraus, Head of Sales stated, “The Cust2Mate platform with embedded Lenovo OEM solution is designed to serve shoppers from the moment they enter the store until they leave-without any friction, lines, or delays.”

#2 Launches Next Generation V2.8 Light Smart Cart

AZ stock hit its 4-month high recently as a key contender for the stock to watch this year. One of the major catalysts behind the latest rally in the stock came about earlier this week when the company announced that it had launched its latest Smart Card model. The product in question is expected to further enhance the current range of offerings from A2Z Smart.

The company announced that the latest version of the model had been created after consulting with some of the major retail companies in the world from the Asian and European markets.

#3 It Will Display Its Smart Cart Line of Products at the NRF 2023 Big Retail Show In NYC

Moreover, earlier on in the month on January 12, the company made another announcement that had come as a positive trigger for the A2Z Smart stock. It announced that it was going to be one of the participants in the NRF Big Retail Show. The company announced at the time that it was going to display its Smart Cart Line at the event.

Considering the recent multiple news, AZ stock should be on your radar as a stock to watch in 2023.

read more
Will AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) Patent News Trigger Further Rally?

Will AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) Patent News Trigger Further Rally?

Jan 18, 2023

AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) stock is flying with a price-volume breakout!!

It was hardly a surprise that the AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) stock went on a major really yesterday and ended up hitting a four-month high following a jump of 29% and closed at a 4-month high. Considering the magnitude of the gains, investors are expected to be in hot pursuit over the course of the coming days.

Why Such a Big Rally?

The news that triggered the rally in the stock was the award of the patent for its proprietary method for the natural processing and modification of gains by the United States Patent and Trademark Office.

AgriFORCE Growing Systems Company Summary

Company Name: AgriFORCE Growing Systems Ltd.

Ticker: AGRI

Exchange: NASDAQ

Website: https://agriforcegs.com/

AgriFORCE Growing Systems Company Summary:

AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI; AGRIW) is an agtech company focused on building an integrated agtech platform that combines the best technology, intellectual property, and knowledge to solve an urgent problem – providing the best solutions to help drive sustainable crops and nutritious food for people around the world.

The AgriFORCE vision is to be a global leader in delivering plant-based foods and products through an advanced and sustainable agtech platform that makes a positive change in the world—from seed to table. Additional information about AgriFORCE is available at: www.agriforcegs.com.

#1 – AgriFORCE Granted Patent Related to its Proprietary Methods for Processing Nutritious Foods Under the UN(THINK)™ Foods Brand

The company is highly innovative and is engaged in the advancement of agricultural technology which could promote sustainable agriculture as well as crop processing operations.

By way of this particular process, it would be possible to turn grains of rice, pulses, and other seeds into fiber-rich, high-protein, and low-starch baking flour products. It is clear to see that it is a patent that could lead to a revolution in the fast-growing nutritious foods space.

It ought to be noted that the unique process had been acquired by AgriFORCE through the acquisition of Manna International Group back in May last year. The acquisition was part of the company’s overall aggressive acquisition strategy and it seems it may have paid off handsomely following the award of the patent.

#2 – AGRI stock Trades Above 20-Day and 50-Day EMA

Tuesday’s big rally has pushed the stock above key moving averages – signaling a short-term momentum trade. The stock is now trading well above the 20-Day and 50-Day EMA of $1.20 and $1.15 respectively.

Moreover, the stock closed at a 4-month high triggering a multi-month price-volume breakout.

#3- Growth Through Acquisition – Delphy Group’s Acquisition In Focus

Last month on December 28 the company announced that it had got shareholder approval for the acquisition of Delphy Group, which is expected to help AgriFORCE in offering its products in the global market easily.

The acquisition is expected to be closed at some point in the coming weeks. The company has also stated that throughout the course of 2023, it expects to witness certain developments which could further accelerate its growth. AgriFORCE remains committed to its aggressive merger and acquisition strategy.

The company said that ” We will continue to drive our M&A strategy to further strengthen our AgTech 2.0 platform.”

#4 Impressive Outlook

The company is projected to bring the first products under UN(THINK) Foods to market. In particular, with the B2B and direct-to-consumer launch of Awakened Flour, and hope to create a new standard for sprouted flours.

Following this, the company plan to launch our Power Flour which will bring superior nutrition with no compromise to consumers. Additionally, they have several other consumer products in the pipeline, for which we intend to provide additional details in 2023.

Moreover, AgriFORCE will start advancing the expansion of Delphy into North America as well as continue to build our Delphy Digital platform and suite of services.

The company noted ” As we look ahead, we believe we have secured the foundational pieces to transform our business in the near term. We believe 2023 will be a pivotal year in the company’s history and that we have laid the foundation in 2022 to achieve major achievements and successes in the coming year.”

read more
Sharps Technology, Inc. (NASDAQ: STSS) Has An Accelerated Near-Term Path Product For The Commercialization & Accelerated Revenue Growth!

Sharps Technology, Inc. (NASDAQ: STSS) Has An Accelerated Near-Term Path Product For The Commercialization & Accelerated Revenue Growth!

Jan 11, 2023

With An Accelerated Near-Term Path For Product Commercialization And Expanded Manufacturing Capacity, Sharps Technology, Inc. (NASDAQ: STSS) Will Have The Ability To Support The Industry With Innovative, Market Leading Injectable Drug Delivery Solutions And Accelerate A Path Towards Revenue Growth.

STSS
Sharps Technology, Inc. (NASDAQ: STSS)

Newly NASDAQ-traded Sharps Technology, Inc. (NASDAQ: STSS) offers innovative injectable syringe solutions to a global healthcare crisis that is not being talked about nearly enough.

  • Most syringes waste a significant amount of injectable medicine which is thrown away with the used needle/syringe.

  • This adds cost and reduces the availability of life-saving injectable drugs for us all. Whether we are looking at a pandemic response, hard-to-manufacture drug products, or managing long-term chronic illness, we can’t afford to waste this precious supply.

  • The problem is sufficiently worrisome that the Federal Government is passing new legislation (January 1, 2023) requiring pharmaceutical companies to pay financial penalties for injectable drugs which are thrown away with the syringe and not injected into the patient.

Sharps Technology Company Summary

Company Name: Sharps Technology, Inc.

Ticker: STSS

Exchange: NASDAQ

Website: www.sharpstechnology.com

Sharps Technology Company Summary:

Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems.

The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features.

These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use.

Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing.

The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.

Sharps Technology STSS

Sharps Technology has agreed to manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.

Jan. 10, 2023

Announces the advancement of the Company’s specialized prefillable syringe (“PFS”) system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.

Braden Miller, Sharps Director of Product Management, commented, “Sharps has developed an alternative high-quality solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution compared to traditional glass syringe systems.

These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which can eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors.

The ability to produce these innovative products using advanced manufacturing techniques creates additional advantages in the areas of quality, performance and safety when compared to similar glass syringe products. We look forward to introducing this line of next generation products to the market.”

Sharps Technology commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.

Dec. 20, 2022

Announced they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.

The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.

Sharps innovative syringe designs provide a beneficial set of features and advantages for the healthcare industry.

These syringe product features include a combination of ultra-low waste, passive and active safety, and reuse prevention.

By combining all these features and building them into a portfolio of syringe offerings, it will create product platforms that can help drive down the cost of healthcare treatments.

Sharps Technology signed of a distribution agreement with partner Nephron Pharmaceuticals

Dec. 13, 2022

Announced the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.

“This distribution agreement opens so many possibilities for Sharps Technology and Nephron Pharmaceuticals,” commented Robert Hayes, Sharps Technology CEO. “The timing is perfect in that we are expanding our ability to supply innovative drug delivery systems at a point when the market is in demand for them. Through this distribution plan, Sharps Technology will be able to deliver increased capacity, driving growth for one of the high value product segments of our business.”

  • Each year almost  20 billion injections are administered, globally and the World Health Organization (WHO) are advocating for the use of low waste syringes, with passive safety devices which engage automatically and have auto disable features.

  • STSS anticipates signing its first product orders any moment now this development will represent a huge milestone for this recently debuted NASDAQ company, and should provide them with a solid foundation for growth.

  • The company has raised $16M to scale operations in the coming quarters as they begin to meet the strong and growing demand for smart safety syringes

The global vaccines market is projected to grow from $61.04 billion in 2021 to $125.49 billion in 2028 at a CAGR of 10.8% in the forecast period, 2021-2028.

Vaccines are the most powerful and cost-effective way to protect billions of people in the world, and according to the WHO, immunization awareness and government initiatives have helped prevent 2-3 million deaths a year.

The Covid-19 outbreak led to a shutdown of syringe manufacturing which in turn led to a supply shortage at a global scale.

Mergers and acquisitions of companies such as STSS are highly attractive and are providing the needed innovation to the vaccine market.

The rise in the need for vaccinations and immunizations, plus a surge in the geriatric population, an increase in the number of surgical procedures, as well as a rise in chronic diseases have contributed to a demand for syringes.

Specialty Syringes – Vial Application 

  • Global Smart Syringe Market @ $14 billion USD by 2026 w10.0%+ CAGR 

  • Types: Auto-Disable Syringes and Safety Syringes

  • Applications: Vaccination and Drug Delivery

  • End Users: Hospitals, HMOs and Clinics

  • Target Markets: North America, Europe, and ROW

  • Sharps Technology listed as a supplier

The Pre-Filled Syringe (PFS)/Ready- To- Fill (RTF) syringe product segment will be a priority for the company through its collaboration with Nephron, and is expected to be a gamechanger for the company.

PRE-FILLED SYRINGES MARKET

  • Pre-filled syringes have emerged as one of the fastest-growing choices for unit-dose medication as the pharmaceutical industry seeks new and more convenient drug delivery methods.

  • With PFS/RTF syringes, pharmaceutical companies are able to minimize drug waste and increase product life span, while patients are able to self-administer injectable drugs at their home instead of the hospital.

Ready-To-Use – Pre-Filled Syringes:

  • Types: Plastic and Type I B/S Glass 

  • Applications: Vaccines, Diabetes, Complex High Value Therapies (Gene-Therapy)

  • End Users: Branded Pharma, CMOs, and Biologics

  • Target Markets: North America

There is a growing demand for efficient and easy-to-use drug delivery devices and increasing efforts of healthcare professionals to reduce hospital errors are the principal factors driving the market growth.

STSS announced over the summer that it had completed its acquisition of Safegard Medical’s syringe manufacturing facility in Hungary.

The manufacturing facility is located 2 hours from Budapest (160km from Budapest Airport)

  • 40,000 sq. ft. factory on 250,000 sq. ft. site

  • 20-year history of safety syringe manufacturing

  • FDA registered since 1999

  • ISO 13485 certified

  • CE Mark approved products

  • Injection molding and assembly expertise

  • ETO on-site sterilization capacity

“The acquisition of our first manufacturing facility is an important milestone in our transformation from an R&D-focused enterprise to revenue-generating commercial operations. With the acquisition now complete, with the addition of further assembly and manufacturing capacity, our team is confident we can deliver world-class products to meet the strong and growing demand for smart safety syringes, a market forecasted to reach $14 billion globally by 2026.”

Robert Hayes, CEO of Sharps Technology

IN SUMMARY

Sharps Technology, Inc. (NASDAQ: STSS) is the newest player in the drug delivery device market to go public and could see tremendous blue-sky growth in its future as it continues to ramp up its commercialization efforts.

  • The Company recently announced a significant partnership with Nephron Pharmaceuticals with an anticipated launch into the market in early 2023.

  • STSS anticipates shipping first orders of vial draw product by the beginning of 2023 and ready to fill product in mid-2023 to create initial revenue in 2023 and profits in early 2024.

  • With the global shortage of syringes that comply with the World Health Organization (WHO) requirements, there is a strategic opportunity for STSS to take market share and support the healthcare industry with a better drug delivery platform.

  • The combination of features and benefits for the Sharps products will save lives and eliminate the waste of critically needed medical treatments and therapies for the industry!

  • There’s a key opportunity for STSS to grab a big piece of the market with its proprietary smart safety syringe technology designed to eliminate two million potentially infectious accidental needlestick injuries, as well as billions of dollars in medicine wasted with today’s inefficient syringes with their low-dead space feature.

To reiterate, the company anticipates signing its first distributor agreement during the fourth quarter of 2022, which could be at any moment!

FULL DISCLAIMER

read more